Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arexvy Lot Consistency Study in Older Adults
NCT05059301Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2021
- Primary completion
- Jan 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of respiratory syncytial virus vaccine, recombinant, adjuvanted in respiratory syncytial virus infection (RSV) (3 arms), sponsored by GSK. Primary endpoint: RSVPreF3 Specific Immunoglobin G Antibody Geometric Mean Concentration at Day 31. Started Oct 2021; status: completed.
02
Drugs
respiratory syncytial virus vaccine, recombinant, adjuvanted
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05059301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05059301.